X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (19) 19
index medicus (15) 15
female (10) 10
male (10) 10
melanoma (10) 10
ipilimumab (9) 9
mutation (8) 8
adult (7) 7
aged (7) 7
analysis (7) 7
oncology (7) 7
advanced melanoma (6) 6
melanoma - drug therapy (6) 6
metastatic melanoma (6) 6
middle aged (6) 6
aged, 80 and over (5) 5
disease progression (5) 5
immunology (5) 5
immunotherapy (5) 5
metastasis (5) 5
nivolumab (5) 5
prospective studies (5) 5
treatment outcome (5) 5
cancer (4) 4
cell biology (4) 4
neoplasm metastasis (4) 4
open-label (4) 4
pembrolizumab (4) 4
survival (4) 4
animals (3) 3
antibodies, monoclonal - administration & dosage (3) 3
antibodies, monoclonal - therapeutic use (3) 3
antineoplastic combined chemotherapy protocols - therapeutic use (3) 3
antitumor-activity (3) 3
biochemistry & molecular biology (3) 3
carcinoma, renal cell - genetics (3) 3
carcinoma, renal cell - pathology (3) 3
care and treatment (3) 3
cell line, tumor (3) 3
cell survival (3) 3
congresses (3) 3
disease-free survival (3) 3
electronic books (3) 3
immune checkpoint inhibitor (3) 3
kidney neoplasms - genetics (3) 3
kidney neoplasms - pathology (3) 3
longitudinal studies (3) 3
management (3) 3
melanoma - immunology (3) 3
mice (3) 3
patterns (3) 3
phenotype (3) 3
prognosis (3) 3
proteins (3) 3
safety (3) 3
toxicity (3) 3
tumors (3) 3
1506 (2) 2
5' untranslated regions (2) 2
abridged index medicus (2) 2
age of onset (2) 2
alleles (2) 2
anti-ctla-4 antibodies (2) 2
anti-pd-1 (2) 2
antibodies (2) 2
antibodies, monoclonal (2) 2
antisense oligonucleotides (2) 2
anwendungssystem (2) 2
architectural design (2) 2
article (2) 2
biomarkers, tumor (2) 2
braf mutation (2) 2
branched evolution (2) 2
breast-cancer (2) 2
cad (2) 2
cancer evolution (2) 2
cancer research (2) 2
cancer-patients (2) 2
carcinoma, renal cell (2) 2
cdve (2) 2
cell carcinoma (2) 2
cell death (2) 2
children & youth (2) 2
chromosome instability (2) 2
chromosomes (2) 2
chromosomes, human, pair 3 (2) 2
chromosomes, human, pair 5 (2) 2
clinical trials (2) 2
clonal evolution (2) 2
computer communication networks (2) 2
computer science (2) 2
computer supported cooperative work (2) 2
computer-aided design (2) 2
conception assistée par ordinateur (2) 2
conception technique (2) 2
cooperative design (2) 2
ctla-4 (2) 2
ctla-4 antigen - antagonists & inhibitors (2) 2
data processing (2) 2
design architectural (2) 2
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Collection Dvlpm't (Acquisitions) - Vendor file (2) 2
Art - Library use only (1) 1
Engineering & Comp. Sci. - Stacks (1) 1
Robarts - Stacks (1) 1
St. Michael's College (John M. Kelly) - 2nd Floor (1) 1
Trinity College (John W Graham) - Oversize (1) 1
UofT at Mississauga - Stacks (1) 1
UofT at Scarborough - Stacks (1) 1
Victoria University E.J. Pratt - Oversize (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer Treatment Reviews, ISSN 0305-7372, 2016, Volume 44, pp. 51 - 60
Highlights • Role of immune checkpoint inhibition in the management of key malignancies. • Description of rates of immune-related adverse events and timing of... 
Hematology, Oncology and Palliative Medicine | Pembrolizumab | Immune-related adverse events | Renal cancer | Ipilimumab | Nivolumab | Lung cancer | Melanoma | Immune-checkpoint inhibitors | OPEN-LABEL | SINGLE-ARM | ANTI-CTLA-4 ANTIBODY | METASTATIC MELANOMA | ONCOLOGY | ADVANCED MELANOMA | LONG-TERM SAFETY | MALIGNANT MESOTHELIOMA | ENTERIC NEUROPATHY | ADVERSE EVENTS | IPILIMUMAB RETREATMENT | Lung Neoplasms - drug therapy | Skin Neoplasms - drug therapy | Humans | Immunosuppressive Agents - therapeutic use | Antibodies, Monoclonal - adverse effects | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Adrenal Cortex Hormones - therapeutic use | Diarrhea - chemically induced | Infliximab - therapeutic use | Drug Eruptions - drug therapy | Antineoplastic Agents - adverse effects | Colitis - chemically induced | Antilymphocyte Serum - therapeutic use | Colitis - drug therapy | Carcinoma, Renal Cell - drug therapy | Chemical and Drug Induced Liver Injury - etiology | Pituitary Diseases - chemically induced | Pituitary Diseases - drug therapy | Antibodies, Monoclonal, Humanized - adverse effects | Drug Eruptions - etiology | Neoplasms - drug therapy | Cyclosporine - therapeutic use | Tacrolimus - therapeutic use | Mycophenolic Acid - analogs & derivatives | Mycophenolic Acid - therapeutic use | Melanoma - drug therapy | Chemical and Drug Induced Liver Injury - drug therapy | Diarrhea - drug therapy | CTLA-4 Antigen - antagonists & inhibitors | Kidney Neoplasms - drug therapy | Thyroiditis - drug therapy | Thyroiditis - chemically induced | Index Medicus
Journal Article
Melanoma management, ISSN 2045-0885, 05/2019, Volume 6, Issue 2, p. MMT16
Other reported presentations involving the CNS are: aseptic meningitis (15% of patients with neurological irAES in Cuzzubbo’s review of 59 clinical trials (9))... 
immune checkpoint inhibitor | neurotoxicity | CTLA-4 inhibitor | melanoma | PD-L1 inhibitor | PD-1 inhibitor | immune-related adverse effect | Encephalitis | Neurotoxicity | Multiple sclerosis | Immunotherapy | Melanoma | Systematic review | Metastasis | Peripheral neuropathy | Cancer therapies
Journal Article
Gut, ISSN 0017-5749, 06/2018, Volume 67, Issue Suppl 1, p. A80
BackgroundImmune check point inhibitors (ICPis) have transformed the treatment landscape for several cancers, but at the cost of triggering ICPi-induced... 
Journal Article
Trends in Urology & Men's Health, ISSN 2044-3730, 07/2016, Volume 7, Issue 4, pp. 8 - 12
Journal Article
by Arce Vargas, Frederick and Furness, Andrew J.S and Solomon, Isabelle and Joshi, Kroopa and Mekkaoui, Leila and Lesko, Marta H and Miranda Rota, Enrique and Dahan, Rony and Georgiou, Andrew and Sledzinska, Anna and Ben Aissa, Assma and Franz, Dafne and Werner Sunderland, Mariana and Wong, Yien Ning Sophia and Henry, Jake Y and O’Brien, Tim and Nicol, David and Challacombe, Ben and Beers, Stephen A and Spain, Lavinia and Wotherspoon, Andrew and Francis, Nicholas and Smith, Amy and Smith, Sean and Smith, Myles and Smith, Elaine and Strauss, Dirk and Hayes, Andrew and Soultati, Aspasia and Stares, Mark and Lynch, Joanna and Fotiadis, Nicos and Fernando, Archana and Hazell, Steve and Chandra, Ashish and Pickering, Lisa and Rudman, Sarah and Chowdhury, Simon and Swanton, Charles and Jamal-Hanjani, Mariam and Veeriah, Selvaraju and Shafi, Seema and Czyzewska-Khan, Justyna and Johnson, Benjamin and Johnson, Diana and Laycock, Joanne and Bosshard-Carter, Leticia and Goh, Gerald and Rosenthal, Rachel and Gorman, Pat and Murugaesu, Nirupa and Hynds, Robert E and Wilson, Gareth and Birkbak, Nicolai J and Watkins, Thomas B.K and McGranahan, Nicholas and Horswell, Stuart and Mitter, Richard and Escudero, Mickael and Stewart, Aengus and Van Loo, Peter and Rowan, Andrew and Xu, Hang and Turajlic, Samra and Hiley, Crispin and Abbosh, Christopher and Goldman, Jacki and Stone, Richard Kevin and Denner, Tamara and Matthews, Nik and Matthews, Sue and Elgar, Greg and Ward, Sophia and Biggs, Jennifer and Costa, Marta and Begum, Sharmin and Phillimore, Ben and Chambers, Tim and Nye, Emma and Graca, Sofia and Al Bakir, Maise and Hartley, John A and Lowe, Helen L and Herrero, Javier and Lawrence, David and Hayward, Martin and Panagiotopoulos, Nikolaos and Kolvekar, Shyam and Falzon, Mary and Borg, Elaine and Simeon, Celia and Hector, Gemma and Aranda, Marie and Novelli, Marco and Oukrif, Dahmane and Janes, Sam M and Thakrar, Ricky and Forster, Martin and Ahmad, Tanya and Lee, Siow Ming and ... and Melanoma TRACERx Consortium and Renal TRACERx Consortium and Lung TRACERx Consortium
Immunity, ISSN 1074-7613, 04/2017, Volume 46, Issue 4, pp. 577 - 586
CD25 is expressed at high levels on regulatory T (Treg) cells and was initially proposed as a target for cancer immunotherapy. However, anti-CD25 antibodies... 
regulatory T cells | tumor immunotherapy | anti-CD25 | Treg depletion | inhibitory Fc receptor | CD25 | tumor microenvironment | Fc gamma receptors | anti-PD-1 | EFFECTOR | RESPONSES | LYMPHOCYTE-ASSOCIATED ANTIGEN-4 | CANCER-PATIENTS | MELANOMA | MONOCLONAL-ANTIBODY | ANTI-CTLA-4 ANTIBODIES | IMMUNOLOGY | ANTITUMOR-ACTIVITY | COMBINATION | GAMMA-RS | T-Lymphocytes, Regulatory - metabolism | Immunotherapy - methods | Humans | Antibodies, Monoclonal - therapeutic use | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Lymphocyte Depletion | Receptors, IgG - metabolism | T-Lymphocytes, Regulatory - immunology | Neoplasms - therapy | Flow Cytometry | Immunoglobulin Fc Fragments - immunology | Antibodies, Monoclonal - immunology | Interleukin-2 Receptor alpha Subunit - immunology | Kaplan-Meier Estimate | Programmed Cell Death 1 Receptor - metabolism | Receptors, IgG - immunology | Protein Binding - immunology | Animals | Neoplasms - immunology | K562 Cells | Cell Line, Tumor | Mice | Antibodies, Monoclonal - metabolism | Programmed Cell Death 1 Receptor - immunology | Neoplasms - pathology | Viral antibodies | Cell death | Analysis | Immunotherapy | Antibodies | T cells | Cancer | Fc receptors | Beer | Immunoglobulins | Lymphatic system | Immune response | Cytokines | Melanoma | Light emitting diodes | Lymphocytes T | Anticancer properties | Depletion | Lymphocytes | Tumors | Immune system | Report
Journal Article
CANCER IMMUNOLOGY IMMUNOTHERAPY, ISSN 0340-7004, 06/2016, Volume 65, Issue 6, pp. 769 - 770
To access, purchase, authenticate, or subscribe to the full-text of this article, please visit this link: http://dx.doi.org/10.1007/s00262-016-1845-2 
ONCOLOGY | IMMUNOLOGY | Antibodies, Monoclonal - therapeutic use | Insulins | Humans | Diabetes Mellitus - drug therapy | Insulin | Diabetes therapy | Index Medicus
Journal Article
Trends in Urology & Men's Health, ISSN 2044-3730, 03/2017, Volume 8, Issue 2, pp. 21 - 25
The last decade has seen significant treatment advances in the management of renal cell cancer, from the availability of oral, targeted therapies to the recent... 
Journal Article
Gut, ISSN 0017-5749, 06/2018, Volume 67, Issue Suppl 1, p. A65
BackgroundImmune checkpoint inhibitors (ICIs) including anti-CLTA-4 (e.g. ipilimumab (ipi)) and anti-PD-1 antibodies (e.g. nivolumab (nivo)) have improved... 
Journal Article
Trends in Urology & Men's Health, ISSN 2044-3730, 07/2016, Volume 7, Issue 4, pp. 8 - 12
The incidence of malignant melanoma is increasing and although men and women are equally affected, men appear to have poorer survival. In this article the... 
Care and treatment | Melanoma | Diagnosis
Journal Article
Journal Article
Gut, ISSN 0017-5749, 06/2018, Volume 67, Issue Suppl 1, p. A66
IntroductionImmune Checkpoint inhibitors (ICPi) have revolutionised the management of melanoma, non-small cell lung cancer and renal cancer. They block... 
Journal Article
Cell, ISSN 0092-8674, 04/2018, Volume 173, Issue 3, pp. 581 - 594.e12
Journal Article
Asia‐Pacific Journal of Clinical Oncology, ISSN 1743-7555, 10/2019, Volume 15, Issue 5, pp. e97 - e102
Aim Targeted therapy (TT) has improved survival for metastatic renal cell carcinoma (mRCC). However, survival is usually limited if brain metastases (BMs)... 
targeted therapy | renal cell carcinoma | brain metastasis | prognosis | survival
Journal Article